Federal grant · project grant (b)
A Miniaturized and Flexible Continuous Glucose Monitoring Platform - Project Summary the Long-term Goal of This Project Is to Develop a Scalable, User-friendly, and Affordable Continuous Glucose Monitoring (CGM) System for Better Diabetes Management. Ims Has Created the World's Smallest Electrochemical Analyte Sensing Platform Using an Application- Specific Integrated Circuit (ASIC) Based on Complementary Metal-oxide Semiconductor (CMOS) Technology. This Design Offers Unique Advantages, Including Extreme Miniaturization, Improved Signal-to-noise Ratio (SNR) for Better Hypoglycemia Accuracy, and On-chip Temperature Calibration for Enhanced Accuracy and Reliability. the System Employs Highly Scalable Semiconductor and Flexible Electronics Manufacturing Methods, Increasing Lot Sizes by Over 1000 Times Compared to Current CGMS, Simplifying Factory Calibration, and Reducing Costs to Improve Affordability and Broaden Usage. We Demonstrated the Core Ims CGM Platform's Function in Humans Through a First-in-human (FIH) Feasibility Study Presented at Ada 2023. Recently, We Verified the Feasibility of the System’s 14-DAY Operation in an Ongoing Human Study. Our Objective in This Grant Is to Optimize the Design by Expanding the Use of Flexible Electronics to Create a First-in-class Band-aid Transmitter, as Requested by Clinical Experts and Users, to Improve Usability and Acceptance Among Minority Populations. This New Flexible Platform Is Named “glucosoft.” This Work Is Significant as It Will Enable a Fundamental Improvement in CGM Usability by Creating the First Truly Flexible Band-aid Transmitter and Decreasing Costs Through a Unified Fabrication Scheme Using Flexible Electronics for Both the in Vivo Sensor and the Skin-worn Transmitter. This Will Be the First Ever CGM With Extremely Thin and Flexible Design, Hence the Reference to “band Aid”. the Team Includes the Original Inventors of the Core Technology From the California Institute of Technology (DR. Nazari, DR. Rahman, MR. Sencan), a Seasoned Researcher in Electrochemical Sensor Technology (bill Van Antwerp, Former Cso of Medtronic Minimed), Regulatory and Ip Expert (john Heithaus, JD), Commercialization Expert (MR. Paul Strasma, Former Ceo of Capillary Biomedical), Clinical Expert (DR. Alan Marcus, MD; Former Chief Medical Officer of Medtronic Diabetes), and Biosensors and Biomaterials Expert (DR. Natalie Wisniewski, PH.D., Former Cto of Profusa, Inc.).
Committed
$275,275
Paid out
$94.8K
34%
Committed, not yet paid
$180.5K
66%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.